Compare BTMD & XTNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BTMD | XTNT |
|---|---|---|
| Founded | 2012 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.7M | 68.9M |
| IPO Year | 2021 | 2009 |
| Metric | BTMD | XTNT |
|---|---|---|
| Price | $2.00 | $0.47 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $2.83 | $1.00 |
| AVG Volume (30 Days) | ★ 216.3K | 147.8K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 722.22 | 125.00 |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $192,219,000.00 | $53,337,000.00 |
| Revenue This Year | $2.03 | N/A |
| Revenue Next Year | $6.58 | $9.30 |
| P/E Ratio | $33.58 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.27 | $0.44 |
| 52 Week High | $4.75 | $0.95 |
| Indicator | BTMD | XTNT |
|---|---|---|
| Relative Strength Index (RSI) | 48.34 | 41.83 |
| Support Level | $1.97 | $0.44 |
| Resistance Level | $2.17 | $0.67 |
| Average True Range (ATR) | 0.14 | 0.03 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 37.58 | 28.18 |
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company provides support to medical practitioners through training, practice development, and operational services to establish and manage hormone therapy centers. Its activities include educating practitioners on identifying and treating hormone-related conditions. The company generates revenues by charging the Biote-partnered clinics fees associated with the Biote Method and from the sale of Biote-branded dietary supplements.
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.